Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Paratek Pharmaceuticals Inc PRTK

Healthcare Industrials Business Services
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult... see more

Recent & Breaking News (NDAQ:PRTK)

A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Earnings, Economic Data

Benzinga.com  August 23, 2017

Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

GlobeNewswire August 22, 2017

Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference

GlobeNewswire August 8, 2017

Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update

GlobeNewswire August 2, 2017

Investor Network: Paratek Pharmaceuticals Inc. to Host Earnings Call

Accesswire August 2, 2017

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire August 1, 2017

Breakfast Technical Briefing on Biotech Stocks -- Aurinia Pharma, Esperion Therapeutics, Paratek Pharma, and Verastem

PR Newswire July 21, 2017

Paratek Pharmaceuticals to Report Second Quarter 2017 Financial Results and Provide Update on Clinical Progress on August 2, 2017

GlobeNewswire July 19, 2017

Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections

GlobeNewswire July 17, 2017

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire July 7, 2017

Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science Conference

GlobeNewswire June 14, 2017

Stocks Under Scanner in the Biotech Space -- Paratek Pharma, Verastem, Alnylam Pharma, and Albany Molecular Research

PR Newswire June 7, 2017

New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections

GlobeNewswire June 3, 2017

Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017

GlobeNewswire May 24, 2017

Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July

GlobeNewswire May 8, 2017

Wall Street's M&A Chatter From May 4: General Mills, Brookdale Senior Living, Allergan-Paratek

Benzinga.com  May 5, 2017

Investor Network: Paratek Pharmaceuticals Inc to Host Earnings Call

Accesswire May 4, 2017

Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update

GlobeNewswire May 4, 2017

Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide Update on Clinical Progress on May 4, 2017

GlobeNewswire April 26, 2017

Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic (PK/PD) Data

GlobeNewswire April 25, 2017